The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     

 Anadys Pharmaceuticals Inc  (ANDS) Trade Now »     Rate ANDS  -  Discuss ANDS  -  Add to Watch List         Graphic_subscribe

       Sector: Healthcare  >  Industry: Biotechnology & Drugs
This is a micro-cap stock and may be a target of manipulation. Always do your research!

SocialPicks Sentiment:

** v.s. other stocks 		This Quarter's Sentiment:
All:
95.0%
Top:
100.0%
Rate ANDS:



ANDS Analysis & Videos »


ANDS: Bull or Bear?

ANDS-Top 10 Best-Rated Micro Cap Stocks: ANDS, COMV, SWIR, OREX, CLRT, WATG, SKH, MHR, OGXI, PNNT (Jun 09, 2010) Graphic_rating_buy ANDS
Foto
62%
http://suprastock.blogspot.com/2010/06/of-market-it-is-rated-... Anadys Pharmaceuticals, Inc. (NASDAQ:ANDS) is the 1st best-rated stock in this segment of the market. It is rated positively by 10 brokerage analysts. It is covered by 12 brokerage analysts.
By  Marian Filo   (-24.55%  risk: aggressive)  06/10/10 5 comments


ANDS Recent news, Product Line Graphic_rating_buy ANDS
N/A

Innovative ideas toward treatment of Hepatitis C and administration of drug orally not injected, product line will lead to a partnership or out right buyout.  Recent FDA re approval for Hepatitis C drug next phase study.  Patients administered drug have shown favorable results to fighting infection and little side effects.  ANDS has capital to take it into 1st Q 2010.

By  gafa   (+26.79%  risk: conservative)  08/15/09 2 comments


FDA Calendar Updates: Anadys, Merck, Schering-Plough Graphic_rating_buy ANDS
Mikerun
73%
Below is a summary of updates to the BioMedReports.com FDA Calendar , which includes a database of 289 entries as of 7/30/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-stage clinical trial results. ...
By  Mike Havrilla   (+1.04%  risk: moderate)  07/30/09 2 comments


Get free stock alert for ANDS:
Your Email Address:


Profits for Anadys A-Ways Off ANDS
We do not see the company becoming profitable in the near future. We are, therefore, maintaining our Hold rating.
By  Zacks.com   (-1.03%  risk: moderate)  06/06/08 1 comment





People Bullish on ANDS

Foto
Marian Filo
Principal
62%
over 3 years ago

mvpindia
Analyst
N/A
over 3 years ago

gafa
Analyst
N/A
over 3 years ago

shashi249
Analyst
N/A
over 3 years ago

Mikerun
Mike Havrilla
Principal
73%
over 3 years ago


People Bearish on ANDS

ROCK-STAR INVESTORS
Rank Name Sharpe Ratio Avg Return Followers
1 noshoes 21.10 +32.13% 538
2 Gerald Greene 18.14 +6.82% 289
3 stockmarketfunding.com 17.66 +22.47% 85
4 akiralegrand 13.47 +13.86% 71
5 anup2104 12.13 +175.56% 106


POPULAR STOCKS
Symbol Company Name Sentiment
TWX Time Warner Inc
NVDA NVIDIA Corp
BA The Boeing Company
AMZN Amazoncom Inc
PFE Pfizer Inc
ETFC E*Trade Financial Corp

TODAY'S HEADLINES

TODAY'S TOP PICKS

 

StreetInsider.com on ANDS


Discussion Wall + Add  

Be the first to start a discussion and earn 2 points.



More Resources

Graphic_arrow1 About Anadys Pharmaceuticals Inc - Answers.com

Graphic_arrow1 Historical Prices - Yahoo

Graphic_arrow1 Message Boards - BoardCentral.com

Graphic_arrow1 More Info:     Yahoo   |   Google   |   Reuters




IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch